Table 2.
The univariate analysis to evaluate the relationship between clinical variables and OS/PFS
| Clinical variables | N | Median OS (months) | 95% CI | Log rank (P-value) | Median PFS (months) | 95% CI | Log rank (P-value) |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Male | 96 | 15.7 | 13.396–18.004 | 0.243 | 9.3 | 7.380–11.220 | 0.328 |
| Female | 35 | 21.9 | 14.598–29.202 | 12.9 | 8.940–16.860 | ||
| Age | |||||||
| <65 | 87 | 16.2 | 14.006–18.394 | 0.128 | 10.3 | 8.371–12.229 | 0.902 |
| ≥65 | 44 | 17.1 | 5.120–29.080 | 10.7 | 5.175–16.225 | ||
| ECOG PS | |||||||
| 0 | 38 | 24.6 | 21.428–27.772 | 0.000* | 16.1 | 14.650–17.550 | 0.000* |
| 1 | 49 | 19.1 | 16.219–21.981 | 12.3 | 9.843–14.757 | ||
| 2 | 44 | 7.1 | 6.017–8.813 | 2.9 | 1.971–3.829 | ||
| Metastatic sites | |||||||
| Multiple organs | 39 | 7.7 | 3.907–11.493 | 0.004* | 2.9 | 2.043–3.757 | 0.083 |
| Viscera# | 78 | 20.4 | 13.800–27.000 | 12.3 | 10.955–13.645 | ||
| Lymph nodes | 7 | 16 | 14.460–17.540 | 8.8 | 7.260–10.340 | ||
| Bones | 7 | 20.7 | 16.594–24.806 | 15.6 | 9.441–21.759 | ||
| Previous therapy | |||||||
| Nephrectomy + immunotherapy | 70 | 22.6 | 16.769–28.431 | 0.004* | 12.4 | 9.530–15.270 | 0.001* |
| Immunotherapy alone | 25 | 19.1 | 11.705–26.495 | 12.3 | 9.208–15.392 | ||
| Nephrectomy alone | 17 | 6.2 | 0.000–16.319 | 5.3 | 1.220–9.380 | ||
| None | 19 | 5.2 | 1.503–8.897 | 3.1 | 2.397–3.803 | ||
Notes:
*
P<0.05 was considered as statistically significant.
#
Viscera only consider the lungs and liver, except for other organs.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival; PFS, progression-free survival.